FGFR4 Genetic Polymorphisms Determine the Chemotherapy Response of Chinese Patients with Non-small Cell Lung Cancer

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2013 Mar 26

PMID 23524567

Citations 7

Authors

Hong-Mei Fang

Gang Tian

Li-Juan Zhou

Han-ying Zhou

Ying-zhi Fang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the relationship of fibroblast growth factor receptor 4 (FGFR4) gene polymorphisms with the response of Chinese patients with non-small cell lung cancer (NSCLC) to chemotherapy.

Methods: A total of 629 patients with Stage III (A+B) or IV NSCLC, as well as 729 age- and gender-matched healthy controls were recruited. All the patients received platinum-based chemotherapy, and the therapeutic effects were evaluated. Three polymorphisms in the FGFR4 gene (rs351855G/A, rs145302848C/G, and rs147603016G/A) were genotyped, and the association between the 3 polymorphisms and the chemotherapy effect was analyzed using SPSS software, version 16.0.

Results: The genotype frequencies of rs145302848C/G and rs147603016G/A were not significantly different between NSCLC patients and healthy controls on one hand, and between the responders and non-responders to the chemotherapy on the other hand. The distribution of AA genotype and A-allele of rs351855G/A was significantly lower in NSCLC patients than in healthy controls. Using patients with the GG genotype as a reference, the AA carrier had a significantly reduced risk for the development of NSCLC after normalizing to age, sex and smoking habits. In NSCLC patients, this genotype occurred more frequently in the responders to the chemotherapy than in non-responders. The chance of being a responder was significantly increased with the AA genotype as compared to G genotype. The AA genotype of rs351855G/A had a better prognosis compared with GA and GG genotype carriers: the overall survival of patients with the AA genotype of rs351855G/A was significantly longer than those with the GG+GA genotype (21.1 vs 16.5 months).

Conclusion: The rs351855G/A polymorphisms of FGFR4 gene can be used to predict the occurrence, chemotherapy response and prognosis of NSCLC.

Citing Articles

Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis.

Kim J, Jeong S, Jang H, Park S, Kim H Front Oncol. 2021; 11:762528.

PMID: 34737965 PMC: 8560792. DOI: 10.3389/fonc.2021.762528.

FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer.

Sasaki N, Gomi F, Yoshimura H, Yamamoto M, Matsuda Y, Michishita M Cancers (Basel). 2020; 12(10).

PMID: 33066597 PMC: 7602396. DOI: 10.3390/cancers12102976.

Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.

Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T Sci Rep. 2020; 10(1):17054.

PMID: 33051476 PMC: 7553969. DOI: 10.1038/s41598-020-73930-3.

An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer.

Moazeni-Roodi A, Sarabandi S, Karami S, Hashemi M, Ghavami S Biosci Rep. 2020; 40(10).

PMID: 33017009 PMC: 7584815. DOI: 10.1042/BSR20192051.

FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan.

Li J, Huang H, Yang P, Chang C, Chao Y, Tsao T Int J Environ Res Public Health. 2020; 17(16).

PMID: 32781755 PMC: 7460457. DOI: 10.3390/ijerph17165694.

References

Wesche J, Haglund K, Haugsten E . Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437(2):199-213. DOI: 10.1042/BJ20101603. View

Perng R, Yang C, Chen Y, Chang G, Lin M, Hsieh R . High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer. 2008; 62(1):78-84. DOI: 10.1016/j.lungcan.2008.02.023. View

Chang A . Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2010; 71(1):3-10. DOI: 10.1016/j.lungcan.2010.08.022. View

Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S . Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res. 2012; 18(14):3972-81. DOI: 10.1158/1078-0432.CCR-11-1531. View

Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S . Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008; 123(11):2574-9. DOI: 10.1002/ijc.23578. View

Yang Y, Zhou Y, Lu M, An Y, Li R, Chen Y . Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol Carcinog. 2011; 51(7):515-21. DOI: 10.1002/mc.20805. View

Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S . Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010; 28(33):4945-52. DOI: 10.1200/JCO.2010.30.5334. View

Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stattner S . Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res. 2012; 72(22):5767-77. PMC: 5455878. DOI: 10.1158/0008-5472.CAN-11-3654. View

Liwei L, Chunyu L, Jie L, RuiFa H . Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis. Urol Int. 2011; 87(2):159-64. DOI: 10.1159/000329069. View

10.

Powers C, McLeskey S, Wellstein A . Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000; 7(3):165-97. DOI: 10.1677/erc.0.0070165. View

11.

Marme F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C . FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann Oncol. 2010; 21(8):1636-1642. DOI: 10.1093/annonc/mdq017. View

12.

Wang J, Yu W, Cai Y, Ren C, Ittmann M . Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia. 2008; 10(8):847-56. PMC: 2481572. DOI: 10.1593/neo.08450. View

13.

Marme F, Hielscher T, Hug S, Bondong S, Zeillinger R, Cacsire Castillo-Tong D . Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer. 2011; 131(4):E586-91. DOI: 10.1002/ijc.27329. View

14.

Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U . Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005; 23(29):7307-11. DOI: 10.1200/JCO.2005.17.350. View

15.

Zhu Q, Liu T . Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study. Mol Biol Rep. 2012; 39(9):8679-85. DOI: 10.1007/s11033-012-1723-8. View

16.

Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M . Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res. 2004; 10(12 Pt 2):4215s-4219s. DOI: 10.1158/1078-0432.CCR-040006. View

17.

Falvella F, Frullanti E, Galvan A, Spinola M, Noci S, De Cecco L . FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009; 124(12):2880-5. DOI: 10.1002/ijc.24302. View

18.

Zhang H, Zhao K, Yang P, Fang Y, Zhang Y, Liu J . Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke. J Int Med Res. 2012; 40(5):1708-14. DOI: 10.1177/030006051204000509. View

19.

Kornmann M, Beger H, Korc M . Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas. 1998; 17(2):169-75. DOI: 10.1097/00006676-199808000-00010. View

20.

Cappuzzo F, Ligorio C, Ligorio C, Toschi L, Rossi E, Trisolini R . EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007; 2(5):423-9. DOI: 10.1097/01.JTO.0000268676.79872.9b. View